Why the study?
Warfarin and NOACs are used to treat LAA thrombus in AF, but NOAC use is limited in patients with renal dysfunction.
Does apixaban resolve warfarin-resistant left atrial appendage thrombus in a patient with end-stage renal disease on hemodialysis?
Does apixaban resolve warfarin-resistant left atrial appendage thrombus in a patient with end-stage renal disease on hemodialysis?
Apixaban may be a viable and safe option for resolving warfarin-resistant left atrial appendage thrombus in patients with end-stage renal disease on hemodialysis.
Apixaban may resolve warfarin-refractory LAA thrombus in ESRD on HD; leaves open need for prospective trials before practice change.
The left atrial appendage (LAA) is the major source of thromboembolism in patients with atrial fibrillation (AF). Warfarin or new oral anticoagulants (NOACs) have been used to treat the LAA thrombus; however, the use of NOACs is limited in patients with renal dysfunction. Here, we report the case of a patient with paroxysmal AF and end-stage renal disease (ESRD) requiring hemodialysis, in whom apixaban successfully and safely resolved a LAA thrombus refractory to warfarin.
No takes yet. Share an insight, caveat, or question.
Yae Min Park (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: